Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.05.23	Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission (RSS)
25.05.23	Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting (Businesswire)
25.05.23	Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 (Businesswire)
18.05.23	FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization (Businesswire)
17.05.23	Pfizer Prices $31,000,000,000 Debt Offering (Businesswire)
15.05.23	Pfizer Announces Proposed Notes Offering (Businesswire)
02.05.23	Pfizer Reports First-Quarter 2023 Results (Businesswire)
27.04.23	U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children (Businesswire)
26.04.23	Pfizer Declares Second-Quarter 2023 Dividend (Businesswire)
13.04.23	Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 (Businesswire)
04.04.23	FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI (Businesswire)
21.03.23	Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts (Businesswire)
16.03.23	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™ (Businesswire)
14.03.23	Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years (RSS)
13.03.23	Pfizer Invests $43 Billion to Battle Cancer (Businesswire)
10.03.23	Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval (Businesswire)
01.03.23	Tilray Brands Sets Sights on Asia: Bringing Award-Winning Craft Beers to Japan’s Premier American Craft Beer Experience Festival (RSS)
28.02.23	Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults (Businesswire)
27.02.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
22.02.23	Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance (Businesswire)
21.02.23	U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review (Businesswire)
16.02.23	Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study (Businesswire)
16.02.23	Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults (Businesswire)
10.02.23	FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib) (Businesswire)
10.02.23	8-K: Report of unscheduled material events or corporate event (RSS)
09.02.23	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
31.01.23	PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE (Businesswire)
17.01.23	Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries (Businesswire)
06.01.23	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children (Businesswire)
03.01.23	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
28.12.22	U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents (Businesswire)
26.12.22	Accelleron-Aktie, Porsche-Aktie & Co.: Das wurde aus den 2022er IPOs (finanzen.ch) Regelmässig wird die Börsenlandschaft durch weitere Unternehmen ergänzt - so auch 2022. Diese Neuankömmlinge standen dabei besonders im Fokus der Anleger.» mehr
21.12.22	Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis (Businesswire)
20.12.22	Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts (Businesswire)
10.12.22	Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial (Businesswire)
09.12.22	Pfizer Declares First-Quarter 2023 Dividend (Businesswire)
09.12.22	Tilray Brands' Stockholders Approve Reverse Stock Split; Company Pauses Implementation as It Evaluates Timing and Stock Price (RSS)
08.12.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (Businesswire)
08.12.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (RSS)
07.12.22	U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults (Businesswire)
06.12.22	Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease (Businesswire)
05.12.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (RSS)
01.12.22	Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day (Businesswire)
18.11.22	4: Statement of changes in beneficial ownership of securities (RSS)
17.11.22	Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection (RSS)
16.11.22	Form 4 78003 (RSS)
11.11.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
30.08.22	So sieht die Aktionärsstruktur beim Corona-Impfstoffentwickler BioNTech aus (finanzen.ch) Der Corona-Impfstoff aus dem Hause BioNTech hat nicht nur die Börse euphorisch gestimmt, sondern auch den Mitgründer und CEO des Konzerns, Ugur Sahin, in die globale Rangliste der Superreichen katapultiert.» mehr
14.03.22	Dividenden-Aktien als Sicherheitsanker: Diese Papiere empfiehlt Jim Cramer (finanzen.ch) Angesichts der derzeitigen Marktturbulenzen könnten sich Anleger solchen Aktien zuwenden, die eine solide Dividende versprechen. Börsenguru Jim Cramer hat deshalb eine Liste von zehn Unternehmen zusammengestellt, die er in diesem Zusammenhang zum Kauf empfiehlt.» mehr
25.02.22	Wie Pfizer von der Coronakrise profitiert: Impfstoff und Corona-Medikament sorgen für Rekordgewinne (finanzen.ch) Einst regierte Pfizer dank seines unverhofften Kassenschlagers Viagra die Pharmabranche. Doch nach Abklingen des Hypes wurde es stiller um den US-Riesen. Die Coronakrise hat Pfizer nun jedoch wieder ganz nach vorn gebracht - der Pharmakonzern ist erfolgreicher als je zuvor.» mehr

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Alcon	61.70	3.70 %	K V
Kuehne+Nagel Int	157.75	3.58 %	K V
Lonza Grp	552.80	3.52 %	K V
Roche Hldg G	288.70	3.51 %	K V
Sika	157.10	3.19 %	K V
ABB	57.08	0.46 %	K V
Swiss Life Hldg	878.60	0.43 %	K V
Swisscom	600.50	0.17 %	K V
Logitech Intl	96.62	-0.98 %	K V

Pfizer Aktie VALOR 1065272 / ISIN ARDEUT111424

Nachrichten zu Pfizer Inc Cert.Deposito Arg.Repr. 0.5 Shs

Aktien Top/Flop

Pfizer Peer Group Nachrichten

Meistgelesene Nachrichten